Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Roche | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Roche

Pharmaceutical sales up 4% YTD

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche
 
YTD Revenues: 34.9 billion CHF (+3%)
 
Comments: Pharmaceutical sales were 27.2 billion CHF, up 4% driven by cancer drugs Avastin, Herceptin, MabThera/Rituxan, Perjeta and Kadcyla, as well as rheumatoid arthritis treatment Actemra/RoActemra. The HER2 breast-cancer franchise, which includes Herceptin, Perjeta and Kadcyla, grew 13%. Avastin sales rose 13% due to recent approvals in ovarian cancer in Europe, colorectal cancer in the U.S. and Europe, and the first approval for newly diagnosed glioblastoma in Japan. Sales in the U.S. were up 11% to 11.4 billion. Sales in Europe were up 4% to 7.0 billion. Sales in Japan were down 16% to 2.5 billion. Diagnostics Division sales were 7.7 billion, up 2%. All numbers are in CHF.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters